Eli Lilly (LLY) Gets FDA Nod for RET Inhibitor in Solid Tumors

This article was originally published on Nasdaq

Eli Lilly LLY announced that the FDA granted accelerated approval to Retevmo (selpercatinib) in adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion, regardless of tumor type. The drug has been approved to

Responses